AKT1 and Familial prostate cancer: The Lan-1 antagonist, which is similar to Lan-2, effectively inhibited leptin-induced phosphorylation of Jak2, Akt and ERK1/2 in a dose-dependent manner in the LNCaP prostate cancer cell line (Samuel–Mendelhson et al. 2011).